Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 20/20 | 0.73 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.73 |
| ▸ | PPIB | P23284 | 12/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PPIF | P30405 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183316 | 0.96 | PPIA (0.80) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL15183344 | 0.94 | PPIA (0.78) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL19861212 | 0.93 | PPIA (0.74) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL15183330 | 0.91 | PPIA (0.81) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL15182952 | 0.91 | PPIA (0.86) | PPIASLCO1B1PPIBPPIF | |
| SCHEMBL15183310 | 0.91 | PPIA (0.81) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL15183374 | 0.90 | PPIA (0.78) | PPIASLCO1B1PPIBPPIF | |
| SCHEMBL19861467 | 0.90 | PPIA (0.78) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL17523723 | 0.89 | PPIA (0.80) | PPIASLCO1B1PPIBCYP3A4CYP2C9 | |
| SCHEMBL15182974 | 0.89 | PPIA (0.82) | PPIASLCO1B1PPIB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | PPIA 403/4885SLCO1B1 438/4885PPIB 35/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PPIA 435/4885SLCO1B1 448/4885PPIB 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.